Versant Ventures

Versant Ventures is a healthcare-only venture firm with $5.5 billion in assets under management and one of the most distinctive operating models in biotech: an in-house company creation infrastructure that generates roughly half of its portfolio companies from scratch rather than sourcing them as external deals. Founded in 1999 and operating from offices in San Francisco, Boston, Toronto, Vancouver, Basel, and Munich, Versant has produced more than 100 successful acquisitions or IPOs across its history, with notable franchises including Audentes Therapeutics (acquired by Astellas for $3 billion), CRISPR Therapeutics (IPO and substantial public market valuation), and Quanticel Pharmaceuticals (acquired by Celgene). The firm’s Discovery Engines, named Ridgeline (Basel) and Highline (New York), comprise in-house multi-disciplinary teams of scientists working in state-of-the-art laboratory facilities to translate academic research and pharma assets into fully formed biotech companies.

The Versant model is unusual in venture for the depth of its operational commitment. The firm seeds new companies with substantial first-round capital, frequently $25 million to $50 million, and re-runs key experiments independently before fully committing to a thesis, importing big-pharma R&D discipline into the venture-backed biotech process. Senior partners and managing directors across the firm include Brad Bolzon (managing director, longtime anchor of the franchise), Tom Woiwode, Clare Ozawa, Carlo Rizzuto, Kirk Nielsen, Jerel Davis, Robin Praeger, and Alex Mayweg, plus a broad bench of partners with operating backgrounds at Genentech, Roche, Novartis, Vertex, and other big-pharma and biotech operators.

The portfolio reads like a who’s who of validated and emerging therapeutics: cell and gene therapy, RNA therapeutics, gene editing, cardiometabolic, oncology, immunology, neuroscience, rare disease, and platform biology. The firm has been particularly active in CRISPR and gene editing, having co-founded CRISPR Therapeutics, and in obesity and metabolic disease through investments and creations across the GLP-1 era. The Discovery Engines have launched companies across all of these categories and have been particularly productive in producing companies that move from formation to clinical proof of concept under Versant operational leadership.

Check sizes are large at formation and Series A. Versant typically commits $25 million to $75 million at company creation and Series A, sometimes funding the company’s first two to three years before raising additional capital. The firm leads at formation and Series A and frequently anchors Series B and C as well, working alongside peer specialists including OrbiMed, Third Rock, F-Prime, RA Capital, and the broader biotech crossover community. Geographic scope is genuinely global with strong US, Canadian, Swiss, and German practices, and the firm has been particularly successful in transatlantic deals where North American academic insights are built into European companies (or vice versa) using the Discovery Engine infrastructure.

Founders who should approach Versant are academic principal investigators with breakthrough scientific platforms, repeat biotech entrepreneurs with new therapeutic theses, and clinician-scientists with translational insights. The firm is particularly well suited for founders who are open to a deep operating partnership where Versant scientists may help validate, refine, or expand the founding thesis through the Discovery Engine. Founders building digital health, devices, diagnostics-only, or non-therapeutic businesses are not the right fit; Versant is decisively a therapeutics company-creation firm. Founders looking for a passive check or quick term sheet should also pitch other firms; Versant’s value-add is high-touch operational partnership, not arms-length capital.

Entry path runs through academic affiliations across major US, Canadian, and European research universities, plus warm introductions from portfolio CEOs, scientific advisors, and peer specialists. Versant partners are at JPMorgan Healthcare, BIO, BIO Europe, AACR, ASCO, ASH, and the major scientific conferences. The firm runs an active scientific advisor network that frequently connects to academic founders. Cold inbound through the website is triaged but converts at low rates without a strong scientific signal. Diligence is rigorous and partner-driven, frequently including hands-on Discovery Engine experimental validation, typically six to twelve weeks from first meeting to formal commitment for novel platforms.

In a pitch, lead with the science, the unmet need, the IP estate, and the platform thesis. Versant partners are deeply technical and many hold MD or PhD degrees in relevant disciplines; they will probe your translational data, your competitive positioning, and your manufacturing plan in detail. Bring rigor and be open to a creation-model partnership where Versant contributes scientific operations and operating leadership across multiple years. The firm’s added value is unmatched in the formation and early company-building stages: in-house Discovery Engine validation, senior operating talent, manufacturing and CMC expertise, and a track record of building companies that scale from preclinical to commercial. Founders willing to partner deeply with a creation-model firm will find Versant one of the most powerful and unusual tier-one investors in biotech, with the capacity to take an academic insight from formation to IPO under a single partnership relationship.